WASHINGTON — A subsidiary of an Indian pharmaceutical company has agreed to pay $500 million fines and civil penalties for selling adulterated drugs and lying about tests to federal regulators, the Justice Department said Monday. The guilty plea by Ranbaxy USA Inc. represents the largest financial penalty by a generic drug company for violations of the Federal Food, Drug and Cosmetic Act, which prohibits the sale of impure drugs, prosecutors said. Ranbaxy, a subsidiary of ...

You Must Log-In or Subscribe to Continue
Individual stories can be found and purchased from our Archives for $2.00